1. Home
  2. SEAT vs OMER Comparison

SEAT vs OMER Comparison

Compare SEAT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vivid Seats Inc.

SEAT

Vivid Seats Inc.

HOLD

Current Price

$6.58

Market Cap

82.9M

Sector

Industrials

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$16.20

Market Cap

628.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEAT
OMER
Founded
2001
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.9M
628.9M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
SEAT
OMER
Price
$6.58
$16.20
Analyst Decision
Buy
Strong Buy
Analyst Count
8
5
Target Price
$32.94
$27.50
AVG Volume (30 Days)
137.3K
3.0M
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$643,775,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.15
$2.95
52 Week High
$100.00
$17.65

Technical Indicators

Market Signals
Indicator
SEAT
OMER
Relative Strength Index (RSI) 36.16 77.16
Support Level $6.40 $8.60
Resistance Level $6.74 $17.65
Average True Range (ATR) 0.49 1.10
MACD 0.10 0.56
Stochastic Oscillator 21.92 84.22

Price Performance

Historical Comparison
SEAT
OMER

About SEAT Vivid Seats Inc.

Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: